True Wealth Design’s Gyre Therapeutics GYRE Stock Holding History

True Wealth Design’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6	Closed	-$47	–	2677
2025 Q1	$47	Buy	+6	New	+$66	﹤0.01%	2398

Other funds holding GYRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

True Wealth Design's GYRE Position: Q2 2025 in Review

True Wealth Design sold out of Gyre Therapeutics (GYRE) in Q2 2025, closing a stake of 6 shares — an estimated $47 sold.

True Wealth Design first reported a position in GYRE in Q1 2025 and held it in 1 quarter. The position peaked at $47 in Q1 2025. 48 funds tracked by Wall St. Rank hold GYRE as of Q2 2025.

True Wealth Design reported no remaining Gyre Therapeutics position as of Q2 2025 after selling out during the quarter.
True Wealth Design sold 6 Gyre Therapeutics shares in Q2 2025, an estimated $47.
True Wealth Design first reported a position in Gyre Therapeutics in Q1 2025 and held it in 1 quarter.
True Wealth Design's Gyre Therapeutics position peaked at $47 in Q1 2025.
48 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2025.

Based on True Wealth Design's 13F filing for Q2 2025, filed 6 Aug 2025.